discomfort and two with worry about abdominal symptoms. Items that loaded onto factor two were concerned with fear that symptoms were caused by a serious underlying illness. Items loading onto factor three were concerned with the fear of symptoms in the context of new experiences, for example trying new foods or having access to toilets in places that someone hasn’t visited before. Both factor one of the VSI and the PHQ-12 were strongly and independently associated with IBS symptom severity, for the group as a whole ($p < 0.001$), and for all four IBS subtypes. However, factors two and three of the VSI were not significantly associated with IBS symptom severity. Of note, most VSI items concerned with overt gastrointestinal symptom-specific anxiety loaded onto these two factors that were not associated with IBS symptom severity.

Conclusions The factor structure of the VSI requires further investigation. Our findings cast doubt on the central role of gastrointestinal symptom-specific anxiety as a driver for symptom severity in IBS. Awareness of both gastrointestinal and extra-intestinal symptoms, however, is strongly associated with symptom severity.

Gastroenterology service

**Abstract O64 Table 1**

<table>
<thead>
<tr>
<th>Intervention</th>
<th>High risk BCS cohort</th>
<th>High risk symptomatic cohort</th>
<th>Low Intermediate risk BCS cohort</th>
<th>Low/Intermediate risk symptomatic cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Groups</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interval changed</td>
<td>21.7%</td>
<td>38.9%</td>
<td>2.7%</td>
<td>3.2%</td>
</tr>
<tr>
<td>Surveillance stopped</td>
<td>23.6%</td>
<td>38.9%</td>
<td>52.6%</td>
<td>84.1%</td>
</tr>
<tr>
<td>No interval change</td>
<td>54.7%</td>
<td>22.2%</td>
<td>44.7%</td>
<td>12.7%</td>
</tr>
</tbody>
</table>
to all those tested. All HCV RNA positive were offered a clinic review 10 days after testing to commence treatment with a pangenotypic antiviral.

**Results** Of the 307 residents in the prison at the time of the event, 305 (99.9%) accepted BBV testing. A total of 98 (32%) were HCV antibody positive, of these 23 were HCV RNA detected (23% of HCV Ab pos and 8% of all tested) in keeping with active HCV. One resident was HIV positive (known) and 4 had positive syphilis serology. None were HBsAg positive. Of the 23 HCV RNA positive residents, 3 were already on antiviral treatment, 17 commenced antivirals and 3 were released before treatment could be initiated (contact planned in the community). One patient was suspected of having cirrhosis. Of the 75 HCV antibody positive but RNA negative residents 40 (53%) were known to have received antiviral treatment already and achieved sustained virological response and 10 (13%) were currently on treatment. Feedback from residents and staff on the way the HITT was conducted was good. A point of care HCV RNA testing machine is now being used to identify HCV infection among new residents to try and maintain ‘elimination’.

**Conclusions** A high intensity test and treat weekend coupled with quick access to antiviral treatment for HCV is a highly effective way to ‘eliminate’ HCV within a prison. However, these sessions require meticulous planning in order to be successful.

**Acknowledgment** All the staff and residents of HMP Low Newton and the Hepatitis C Trust.

---

**066 OUTCOME OF INVESTIGATION FOR SUSPECTED MALIGNANCY IN PATIENTS WITH IRON DEFICIENCY ANAEMIA WITHOUT GASTROINTESTINAL SYMPTOMS**

1Gwilym Webb*, 2Thomas Chapman, 3Brian Shine, 1Jack Satsangi, 1Antony Ellis.

1Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford, UK; 2Nuffield Department of Clinical Sciences, University of Oxford, Oxford, UK; 3Department of Computing and Informatics, University of Oxford, Oxford, UK.

10.1136/gutjnl-2020-bsgcampus.66

**Introduction** Iron deficiency anaemia (IDA) without additional gastrointestinal (GI) symptoms is common. Due to the association with GI malignancy, investigation of the upper and lower GI tract is recommended in older adults with IDA. However, rates of specific diagnoses are incompletely defined, and criteria to permit rationalisation of investigation are unclear. The yields of repeated investigation and of testing for coeliac disease (CD) are also uncertain.

**Methods** Cohort study derived from a prospectively collected referrals database of patients with IDA and suspected cancer from two UK hospitals in a single NHS Trust over a 52-month period.

**Results** 5702 consecutive referrals were assessed and, after exclusions, 2035 patient referrals for IDA without additional GI symptoms were assessed. 1118 (54.9%) were women; median age was 74 years (IQR 66–81).

Cancer was diagnosed in 147 (7.2%) and luminal GI cancer in 120 (5.9%). For luminal cancers, the site was colorectal in 103 (5.0% of all patients), gastric in 11 (0.5%) and oesophageal in 6 (0.3%). Other diagnoses made in ≥1% were benign upper GI ulceration in 77 (3.8%), ulcerative colitis in 35 (1.7%), and CD in 21 (1.0%). No major diagnosis was found in 1706 (83.8%).

Those with luminal cancer were older (78 vs 74 years; p<0.001), more anaemic (Hb 89 vs 101 g/L; p<0.001), had higher CRP (38 vs 5.8 mg/L; p<0.001), lower ferritin (14 vs 15 µg/L; p=0.012), lower transferrin saturation (7 vs 9%; p<0.001), lower MCV (79.8 vs 83.2 fL; p<0.001) and lower MCHC (296 vs 302 g/L; p<0.001), and were more likely to be male (53.7% vs 44.5%; p=0.048). The single most discriminative variable for predicting luminal cancer was haemoglobin deficit (AUROC 0.64).

**Abstracts**

**067 THE DEVELOPMENT OF A WEB-BASED APPLICATION TO PREDICT THE RISK OF GI CANCER IN IDA**

1Orouba Almilaji*, 2Vegard Engen, 3Peter Thomas, 4Jonathon Snook. 1Clinical Research Unit, Bournemouth University, Bournemouth, UK; 2Gastroenterology Unit, Poole Hospital NHS Foundation Trust, Poole, UK; 3Department of Computing and Informatics, Bournemouth University, Bournemouth, UK

10.1136/gutjnl-2020-bsgcampus.67

**Introduction** Gastrointestinal (GI) malignancy is a common finding in iron deficiency anaemia (IDA), with a prevalence of about 8%. We have previously reported and validated an algorithm for predicting the risk of GI malignancy in IDA – the IDIOM score. This was derived by logistic regression analysis based on four independent and objective clinical parameters - age, sex, mean corpuscular volume (MCV), and haemoglobin concentration (Hb). To facilitate the clinical use of this algorithm, a software application has been developed, with a view to providing free and simple access to healthcare professionals in the UK.

**Methods** A detailed requirements analysis for intended users of the application revealed the need for an automated tool in which anonymised, individual, patient data is entered and GI cancer risk is calculated and displayed. The solution needed to be user-friendly and platform independent, and needed to facilitate future communication with the development team. Human-centred design (HCD) was employed to develop the solution, focusing on the users and their needs, whilst ensuring that they are provided with sufficient details to appropriately interpret the risk score. To evaluate usability, standard usability questionnaire applied. Participants include healthcare professionals such as IDA nurse specialists, gastroenterologists, etc.

**Results** Predict GI Cancer in IDA has been developed using R Shiny as a web-based application enabling access from...